CEO Pay Mostly Up In India In Year Of C-Suite Exits
Most CEOs/MDs at leading listed foreign and domestic drug firms in India took home bigger pay packages in 2021-22, a period that also saw several top-level exits including at Abbott, Pfizer and Sanofi. Scrip examines some of the wider trends around executive compensation.
You may also be interested in...
Big Pharma Restructures Commercial Teams In India
More foreign pharma firms, this time Sanofi and GSK, are reorganizing sales and marketing efforts accompanied by layoffs in India. Scrip talks to experts about what’s driving the right-sizing and the wider trend.
Big Pharma Rescripts India Playbook
Big pharma appears to be resetting operations in India fueling some concerns of waning interest. In Vivo looks at what the realignment means or doesn’t.
GSK India Chief On Pandemic Decisions, Refreshing The Portfolio
GSK India managing director Sridhar Venkatesh outlines how the company navigated pandemic-related turbulence and “stuck its neck out” to ensure uninterrupted supplies of key drugs. The executive also discusses launch prospects for products including Xevudy in India and an intent to “refresh” the company’s vaccines portfolio.